Journal of Integrative Oncology最新文献

{"title":"Time-restricted Eating to Address Cancer-related Fatigue among Cancer Survivors: A Single-arm Pilot Study.","authors":"Amber S Kleckner, Brian J Altman, Jennifer E Reschke, Ian R Kleckner, Eva Culakova, Richard F Dunne, Karen M Mustian, Luke J Peppone","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Purpose: </strong>Cancer-related fatigue is a prevalent, debilitating condition that can persist for months or years after treatment. In a single-arm clinical trial, the feasibility and safety of a time-restricted eating (TRE) intervention were evaluated among cancer survivors, and initial estimates of within-person change in cancer-related fatigue were obtained.</p><p><strong>Methods: </strong>Participants were 4-60 months post-cancer treatment, were experiencing fatigue (≥ 3 on a scale 0-10), and were not following TRE. TRE entailed limiting all food and beverages to a self-selected 10-h window for 14 days. Participants reported their eating window in a daily diary and completed the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Brief Fatigue Inventory (BFI), and symptom inventory pre- and post-intervention. This study was pre-registered at clinicaltrials.gov in January 2020 (NCT04243512).</p><p><strong>Results: </strong>Participants (n=39) were 61.5 ± 12.4 years old and 1.8 ± 1.3 years post-treatment; 89.7% had had breast cancer. The intervention was feasible in that 36/39 (92.3%) of participants completed all questionnaires and daily diaries. It was also safe with no severe adverse events or rapid weight loss (average loss of 1.1 ± 2.3 pounds, <i>p</i>=0.008). Most adhered to TRE; 86.1% ate within a 10-h window at least 80% of the days, and the average eating window was 9.33 ± 1.05 h. Fatigue scores improved 5.3 ± 8.1 points on the FACIT-F fatigue subscale (<i>p</i><0.001, effect size [ES]=0.55), 30.6 ± 35.9 points for the FACIT-F total score (<i>p</i><0.001, ES=0.50), and -1.0 ± 1.7 points on the BFI (<i>p</i><0.001, ES=-0.58).</p><p><strong>Conclusion: </strong>A 10-h TRE intervention was feasible and safe among survivors, and fatigue improved with a moderate effect size after two weeks.</p><p><strong>Limitations: </strong>This was a single-arm study, so it is possible that expectation effects were present for fatigue outcomes, independent of effects of TRE <i>per se</i>. However, this feasibility trial supports evaluation of TRE in randomized controlled trials to address persistent cancer-related fatigue.</p>","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"11 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33466930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiota behavior, low carbohydrate dietary intake and cancer.","authors":"Leo Nissola","doi":"10.37421/JIO.2020.S1.006","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.006","url":null,"abstract":"Gut microbiota is a key intermediary between diet and host physiology, modulating several metabolic and neurological signaling pathways. Microbiota plays a key role in digestion, metabolism and behavior as well as microbial response to diet. Dysbiosis of gut microbiota has been strongly related to cancer. Ketogenic diet alters the gut microbiota and protects against multiple chronicle diseases and recent studies have linked ketogenic diet with cancer prevention. It is known that over 30 percent of all cancers can be prevented by lifestyle and dietary measures. Obesity, nutrient sparse foods such as concentrated sugars and refined flour products impairs the glucose metabolism. The hypothesis that cytotoxicity induced by glucose deprivation in cancer cells is mediated by mitochondrial superoxide and H2O2 was confirmed by exposing glucose-deprived transformed human fibroblasts to electron transport chain blockers (ETCBs), known to increase mitochondrial superoxide and H2O2 production by a wide number of researchers. Therefore, glucose deprivation in the presence of ETCBs enhanced oxidative stress as well as cell death in several different human cancer cell lines (PC-3, DU145, MDA-MB231, and HT-29). Low fiber intake, consumption of red meat, and imbalance of omega 3 and omega 6 fats contribute to an increase in overall cancer risk in both genders. Studies have show that when a diet is well balanced, it is likely that there would be at least a 60 percent decrease in breast, colorectal, and prostate cancers. Improving metabolites and immunological anticancer profile by k-PBD. There’s robust evidence that shows prolonged fasting, fastingmimicking diet (FMD) and ketogenic diet demonstrates a strong usefulness as adjuvants in cancer therapy.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"61 1","pages":"6-6"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89574892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PROGNOSTIC IMPORTANCE OF MOLECULAR GENETIC MARKERS: Ki67, Bcl2, and p53 IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER","authors":"Karimova N.S","doi":"10.37421/JIO.2020.S1.004","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.004","url":null,"abstract":"Summary. In biopsy preparations, there are 30 patients with cervical cancer at the IIb-IIIb clinical stages. A study in patients with locally advanced cervical cancer showed that a high expression level of Ki67 proliferation in primary patients, elevated levels of p53 protein before carrying out correlate with an unfavorable prognosis, which makes it possible to use these indicators in monitoring the course of the disease. It was shown that prior to the initiation of antitumor treatment, the expression level of Ki67 was as high as possible in those patients who subsequently showed progression of the disease, and reached 85%. The expression level of Ki67 and p53 protein was shown to correlate with indicators of tumor progression. The aim of the study was:  In accordance with the purpose of the study outlined above, the expression level of molecular biological markers Ki67, Bcl2, p53 and their prognostic value in patients with locally advanced cervical cancer who received complex treatment were assessed. Material and methods: 30 patients with locally advanced cervical cancer with IIB – IIIA-B stage who received chemoradiotherapy in ССncer center from 2014 to 2017 were examined. The stages of the disease before the start of treatment were carried out in accordance with the international classification of TNM (seventh revision 2009) and in accordance with the classification of the International Federation of Obstetricians-Gynecologists classification (FIGO, 2011). The diagnosis of the disease in all cases verified histological. Morphologically, all women were diagnosed with squamous cell carcinoma. The possibilities of the proliferative activity marker Ki67, p53 protein, Bcl2 in determining the prognosis of the disease, locally advanced cervical cancer were studied. The material of the study was cervical All patients underwent 3 courses of neoadjuvant polychemotherapy with 21 day intervals, according to the scheme: Cisplatin 100 mg 1 day, Fluorouracil 1000 mg 1-4 days.Then, after computerized topometry of the pelvic organs, planning of combined radiation therapy was carried out, including remote gamma therapy and intracavitary brachytherapy. Remote irradiation was carried out on a gamma therapeutic apparatus (TERABALT type 80 model SCS 2012 Czech Republic) in the standard fractionation mode (daily 5 times a week Single Focal Dose 2 Gy to Total Focal Dose 46 Gy). Intracavitary radiotherapy was performed on a BEBIG brachytherapy device - MULTISOURSE Co60 2013. (Germany) in fractional mode Single Focal Dose 5 Gy, eq Total Focal Dose to point A up to 70-90 Gy, to point B 50-58 Gy. The initial expression of the listed immunohistochemical markers in the tumor and prior to chemo-radiotherapy was evaluated. The immunohistochemical study was carried out according to a standard procedure on dewaxed sections of cervical tissue blocks obtained from resection specimens or cervical biopsies. A pathologist to clarify the histological diagnosis and the correspond","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"93 1","pages":"4-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74818483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation protection during PRRT therapy in NGHA","authors":"N. Senhou","doi":"10.37421/JIO.2020.S1.010","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.010","url":null,"abstract":"Radiation protection in medicine covers in principle, medical exposure, occupational exposure, and public exposure in association with various clinical circumstances. Medical exposure involves not only patients but also their relatives and medical staff. Peptide receptor radionuclide therapy (PRRT) is a molecular targeted therapy used to treat neuroendocrine tumors (NET). In National Guard Hospital in Saudi Arabia the PRRT therapy is kind of new treatment and the radioprotection for such treatment was unknown because of the lack of reference or lectures, in some cases it may be considered as a low contamination treatment because it’s a beta emission, PRRT delivers high doses of radiation to tumors in the body to destroy or slow their growth and reduce disease side effects, Therapeutic procedures with beta emitters are growing. The purpose of this topic is to report on the current state of PRRT, to clarify the issues of radiation protection associated with PRRT, and to show future prospects. Medical staff is often not aware of the high risk of exposure to beta radiation, inappropriate dose meters available or used can make it more complicated, the personal dose meters used often are not worn properly. Skin dose of staff during labelling(preparation) and infusion (administration) should be done carefully because extremity exposure of technicians during preparation may exceed dose limit if safety standards are not strictly kept. PRRT requires deliberate radiation protection standards as it uses unsealed radionuclides and gives therapeutic radiation doses in humans. the goal of this topic is the proposal of large variations of individual practices during preparation and administration and to imply options for improving radiation safety","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"6 1","pages":"10-10"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81907315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of oral immunotherapy in a case of metastatic breast cancer.","authors":"C. Ambrose","doi":"10.37421/JIO.2020.S1.003","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.003","url":null,"abstract":"February 13, 2019 marked the 5th anniversary of The Male Breast Cancer Coalition (MBCC).  This non-profit and awareness foundation was established with the objectives of saving lives through advocacy, education and a complete resource access of any and all support facilities and clinical information leading to the diagnosis, treatment and prevention of Male Breast Cancer. Origins of the MBCC came from the partnership between MBCC President and Co-founder, Cheri Ambrose of New Jersey and co-founder Bret Miller of Kansas City who is recorded as the youngest male worldwide to contract breast cancer. Bret was just 17 years old when he found a lump during a high school sports physical. For six years he was told by various doctors that it was nothing to worry about, just calcium that would dissipate as he got older. Bret underwent a mastectomy for breast cancer at the age of 24.  He promised his doctor that if cured, he would become the face of breast cancer for me. He started his own awareness foundation, the Bret Miller 1T Foundation with his mother Peggy Miller as his manager and was attending many of the local 5k races and breast cancer events in Kansas City in an effort to bring awareness to the risk men face. Cheri had been working at her own organization in New Jersey known as the Blue Wave.  The Blue Wave was born out of a need for awareness after a very dear friend had been diagnosed with breast cancer.  He went from being a vibrant, outgoing person into a virtual hermit, shutting himself off from everyone due to embarrassment of having a women’s disease. Once connecting, through social media and an hour-long phone call with Peggy Miller, Bret’s mother and foundation manager, the two knew there was so much more they could do together and joined forces and never looked back.  To date touching the lives of over 500 men diagnosed with breast cancer around the world.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"7 1","pages":"3-3"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81491991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pelvic Pain is Correlated with Vitamin D Serum Levels in Ovarian Endometriosis","authors":"M. Manero, J. Alcázar, P. Ortega","doi":"10.37421/JIO.2020.9","DOIUrl":"https://doi.org/10.37421/JIO.2020.9","url":null,"abstract":"Objective: To determine whether Vitamin D serum levels are correlated with pelvic pain in patients with ovarian endometriomas. Design: Prospective study. Setting: Tertiary-care university hospital. Patient(s): vitamin D serum levels were prospectively analyzed in 43 patients (group A, asymptomatic patients or patients with mild dysmenorrhea; group B, moderate dysmenorrhea and group C, severe dysmenorrhea and/or chronic pelvic pain and/or dyspareunia) who were diagnosed for cystic ovarian endometriosis to assess whether a correlation exists between Vitamin D serum levels and pelvic pain. Intervention(s): Vitamin D serum levels determination. Main outcome measure(s): Vitamin D serum levels and pelvic pain. Result(s): From 43 patients, five cases were ultimately excluded because patients didn´t continuous). The mean (± SD) vitamin D serum levels in group A were 26,9 ± 04.17 pg/mL in group B were 16,2 ±1,4 pg/mL. and group C 10,4 pg/ml ± 2,4 pg/ml Conclusion(s): Pain symptoms in ovarian endometriosis is correlated with vitamin –D serum levels.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"23 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82960654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge on colorectal cancer prevention among adults attending at a tertiary level hospital","authors":"Sachita Budhathoki, J.Pokharel","doi":"10.37421/JIO.2020.S1.011","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.011","url":null,"abstract":"Colorectal cancer ranks among the third most common cancer worldwide, second in terms of mortality due to cancer and has shown an increasing trend of incidence in Asian region lately.    In Nepal, It is among the top five most common cancers in both males and females. Over the next ten years, countries in the low- income Asia pacific region including Nepal are projected to have the highest colorectal cancer  growth rates of 70%. Owing to the growing burden, there is demand for more research in the field and hence strategies to increase the knowledge on colorectal cancer. The American cancer society asserts that colorectal cancer is common after age 50 and its screening should start after age 45. This study aimed to assess the level of knowledge on colorectal cancer including knowledge on preventive lifestyle and screening tests among adults. A cross sectional descriptive study was conducted from 2018 october- 2019 January among 110 non- cancer patients and adults aged 40-75 years attending Nepal Medical college Teaching Hospital. Non-probability purposive sampling was done. Structured interview questionnaire adopted from standard bowel cancer awareness measure (CAM) developed by cancer research UK was used for data collection. Frequency distribution, mean values and chi-square value were computed for statistical analysis. Results show that 81.8% had heard of colorectal cancer in their lifetime while 18.2% had never heard of it before. The main source of information was friends (47.7%)  Of those who had heard of colorectal cancer, 92.2% believed colorectal cancer is preventable while 23.3% had in fact heard about colorectal cancer screening tests and mean knowledge percentage on the domain was only 14.44%. Mean knowledge percentage was found highest (74.6%) for knowledge regarding preventive lifestyle practices. Majority (65.6%) had moderate level of knowledge, 24.4% had inadequate knowledge while only 10% had adequate level of knowledge. Significant statistical association was not found between level of knowledge and selected demographic variables like age, sex, education, occupation (p<0.05) There is need of extensive public awareness programs on colorectal cancer with a focus on screening tests to fill the gaps of knowledge and promote utilization of early screening methods for prevention. Health care professional should be able to provide planned, structured health teaching on colorectal cancer to disseminate authentic information on the topic.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"72 1","pages":"11-11"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85162010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of Vitronectin as a potential Serum Biomarker for Breast Cancer Prognosis","authors":"M. Srivastava, A. Bera","doi":"10.37421/JIO.2020.S1.008","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.008","url":null,"abstract":"Introduction: Breast Cancer is the most common form of cancer in women worldwide, impacting nearly 2.1 million women each year. In 2018, nearly 627,000 women died of breast cancer, which accounts for 15% of all cancer deaths. Identification of new biomarkers could be key for early diagnosis and therefore, increase the survival.  Vitronectin, a glycoprotein that is abundantly found in serum, extracellular matrix, and bone, binds to integrin alpha V beta 3, and promotes cell adhesion and migration. Current studies indicate that patients with amplified Vitronectin copy-number have lower survival rates than patients without amplified Vitronectin. In this study, we focused on the role of vitronectin in breast cancer survival and its functional role as a non-invasive biomarker for early stage and stage specific breast cancer detection. Materials and Methods: To confirm that the expression of vitronectin is amplified in breast cancer, a total of 240 serum samples (n=240) from breast cancer patients were analyzed using the Reverse Phase Protein Array (RPPA) technique. Of the 240 samples, 120 samples were of African American descent, while the other 120 were of Caucasian American descent.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"63 1","pages":"8-8"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75253546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health Beliefs on the Behavioral Adoption of Mammography Screening: A Path Analytic Model","authors":"M. Gordin, H. Philip","doi":"10.37421/JIO.2020.S1.014","DOIUrl":"https://doi.org/10.37421/JIO.2020.S1.014","url":null,"abstract":"To study the T-cell repertoire during tumor progression, we followed 10 female mice of a transgenic mouse strain that expresses the un-activated rat neu (Erbb2) oncogene, along with 5 control mice. These mice develop mammary tumors spontaneously over 5-8 months. To quantify the peripheral T cell repertoire, we extracted T cells from blood, every month, over the period of 9 months. Cells from these samples were sorted and later processed through a cDNA TCR С and С library preparation protocol using single-molecule barcoding and then NGS sequenced. We were able to use the repertoire to classify tumor and non-tumor mice, using their immunological repertoire. Using feature selection algorithms, we were able to provide superior classification using a small subset (3 to 6 clones) of the T cell repertoire. Thus, machine learning and feature selection allowed us to reduce the hundreds of thousands of TCR alpha and beta sequences obtained during repertoire sequencing, to a set of six clones, with which we can identify the source of a blood sample as tumor or control. We can further stratify older transgenic mice (older than 5 months) and those of older control mice, using the same small T cell clones’ subset. This latter classification has been obtained with as little as three T cell clones.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"67 1","pages":"14-14"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82189563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Botulinum Toxin Usefulness in the Treatment of Drooling in Childhood","authors":"P. Borrego","doi":"10.35841/0971-9032.349-354","DOIUrl":"https://doi.org/10.35841/0971-9032.349-354","url":null,"abstract":"Introduction: Drooling is a common and severe problem in different kind of disorders. It affects both adults and children and it is the cause for respiratory infections or dermal complications as minor social participation. Ultrasound botulinum toxin injections could be a successful option to reduce excessive sialorrhea in children independently whose origin it has. Methods: Retrospective-descriptive survey. Period study: 2010- 2019. Inclusion criteria: patients under 18 on severe drooling. Measure units: demographic data, glands injected, botulinum toxin dosage, side effects, intensity and frequency drooling scale (IFDS), and daily changes of bibs/tissues before and 1 month after ultrasound guided injection, use of sedation during procedure and feeding mode. Intervention was performed with ultrasound guidance of salivary glands (10 MHZ linear transducer: submental acoustic window of submaxilar glands and transverse scans of parotid glands) Results: 67 patients, 58,2% females. Mean age 9,03 (limits: 4-14 years). 46,3% were Cerebral Palsy patients. The most frequently gland infiltrated was submaxilar (53,7%). They showed severe drooling (65,7%) or profuse drooling (26,9%) and 88,1% constantly drooled pre treatment. Botulinum toxin total dosage average used, was 53,78 IU (Parotids/ submaxilar mean dosage: 23,06 IU/ 19,49 IU respectively). 30 day post treatment assessment: 6% no drooling and 68,6% mild or moderate drooling, 34,1 % occasionally drooled. Statistical significative difference (p <0,05%) pre-post infiltration. Daily bibs changes post-injection reduction: 48%. Non-response to toxin injection in ten of the treatment sessions: 14,9% cases. Side-effects: 2,98% (hematoma/ mild dysphagia). No differences observed by glands number injected, sedation procedure or underlying disease. Conclusions: Ultrasound botulinum toxin injections in children with severe drooling, demonstrated clinical improvement in reduction on saliva. The usefulness didn´t depend on the disease that originated the sialorrhea. Some children failed to respond to the treatment due probably to insufficient dosage, inadequate diagnosis or uncontrolled secondary drooling factors. Good results were possible with injections of two glands (instead of four), reducing side effects possibility.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"40 1","pages":"6-6"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75657260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}